Published in Ann Neurol on January 01, 2008
New natural history of interferon-beta-treated relapsing multiple sclerosis. Ann Neurol (2007) 3.87
Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med (2008) 7.25
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med (2008) 6.08
Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. JAMA (2012) 5.11
Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev (2011) 3.44
Accuracy of magnetic resonance imaging for the diagnosis of multiple sclerosis: systematic review. BMJ (2006) 2.95
Lack of evidence for use of glatiramer acetate in multiple sclerosis. Lancet Neurol (2004) 2.70
Longitudinal follow-up of "benign" multiple sclerosis at 20 years. Neurology (2007) 2.39
Comparing the linkage maps of the close relatives Arabidopsis lyrata and A. thaliana. Genetics (2004) 2.30
Vascular aspects of multiple sclerosis. Lancet Neurol (2011) 2.09
Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis. Ann Neurol (2010) 2.07
The natural history of secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry (2010) 1.89
The incidence of stroke mimics among stroke department admissions in relation to age group. J Stroke Cerebrovasc Dis (2008) 1.75
Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients. J Neurooncol (2007) 1.73
Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis. Cochrane Database Syst Rev (2015) 1.70
Moderate hyperglycaemia is associated with favourable outcome in acute lacunar stroke. Brain (2007) 1.67
Beta 2-adrenoceptor involvement in inflammatory demyelination and axonal degeneration in multiple sclerosis. Trends Pharmacol Sci (2004) 1.60
Safety of antiplatelet therapy prior to intravenous thrombolysis in acute ischemic stroke. Arch Neurol (2008) 1.59
Optimizing cutoff scores for the Barthel index and the modified Rankin scale for defining outcome in acute stroke trials. Stroke (2005) 1.55
Interferon β for secondary progressive multiple sclerosis: a systematic review. J Neurol Neurosurg Psychiatry (2012) 1.54
Interleukin-6, a mental cytokine. Brain Res Rev (2011) 1.53
Cerebral autoregulation in stroke: a review of transcranial Doppler studies. Stroke (2010) 1.51
Acetylsalicylic acid and acetaminophen to combat elevated body temperature in acute ischemic stroke. Cerebrovasc Dis (2003) 1.49
Household water source and the risk of childhood brain tumours: results of the SEARCH International Brain Tumor Study. Int J Epidemiol (2004) 1.49
Lack of association between serum uric acid levels and outcome in acute ischemic stroke. J Neurol Sci (2012) 1.47
Keeping cell identity in Arabidopsis requires PRC1 RING-finger homologs that catalyze H2A monoubiquitination. Curr Biol (2010) 1.38
Spontaneous intracranial hypotension with deep brain swelling. Brain (2007) 1.36
Incidence and prevalence of multiple sclerosis in the Americas: a systematic review. Neuroepidemiology (2013) 1.31
Insulin-like growth factor I: a potential neuroprotective compound for the treatment of acute ischemic stroke? Stroke (2009) 1.19
Meningiomas invading the superior sagittal sinus: surgical experience in 108 cases. Neurosurgery (2004) 1.19
Methylation of O6-methylguanine DNA methyltransferase and loss of heterozygosity on 19q and/or 17p are overlapping features of secondary glioblastomas with prolonged survival. Clin Cancer Res (2007) 1.19
Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review. Neurology (2012) 1.17
Mental comorbidity and multiple sclerosis: validating administrative data to support population-based surveillance. BMC Neurol (2013) 1.17
Cigarette smoking and progression in multiple sclerosis. Neurology (2007) 1.15
VAL- and AtBMI1-mediated H2Aub initiate the switch from embryonic to postgerminative growth in Arabidopsis. Curr Biol (2013) 1.14
Seizures in multiple sclerosis. Epilepsia (2008) 1.11
Survival of 793 patients with amyotrophic lateral sclerosis diagnosed over a 28-year period. Amyotroph Lateral Scler Other Motor Neuron Disord (2004) 1.11
Dietary interventions for multiple sclerosis. Cochrane Database Syst Rev (2012) 1.10
Interferon beta and long-term disability in multiple sclerosis. JAMA Neurol (2013) 1.08
Safety of disease-modifying drugs for multiple sclerosis in pregnancy: current challenges and future considerations for effective pharmacovigilance. Expert Rev Neurother (2013) 1.07
Rising prevalence of vascular comorbidities in multiple sclerosis: validation of administrative definitions for diabetes, hypertension, and hyperlipidemia. Mult Scler (2012) 1.07
Prokaryotic phylogenetic diversity and corresponding geochemical data of the brine-seawater interface of the Shaban Deep, Red Sea. Environ Microbiol (2002) 1.07
The utility of administrative data for surveillance of comorbidity in multiple sclerosis: a validation study. Neuroepidemiology (2012) 1.05
White-matter astrocytes, axonal energy metabolism, and axonal degeneration in multiple sclerosis. J Cereb Blood Flow Metab (2012) 1.04
Progression in multiple sclerosis: further evidence of an age dependent process. J Neurol Sci (2007) 1.04
Structural and functional neuroimaging in mild-to-moderate head injury. Lancet Neurol (2007) 1.04
Cancer risk in multiple sclerosis: findings from British Columbia, Canada. Brain (2012) 1.03
The natural history of primary progressive multiple sclerosis. Neurology (2009) 1.02
Insulin-like growth factor I serum levels influence ischemic stroke outcome. Stroke (2011) 1.02
Tremor in multiple sclerosis. J Neurol (2007) 1.01
Diagnosis of asymptomatic natalizumab-associated PML: are we between a rock and a hard place? J Neurol (2014) 1.01
In situ growth of the novel SM1 euryarchaeon from a string-of-pearls-like microbial community in its cold biotope, its physical separation and insights into its structure and physiology. Arch Microbiol (2003) 1.00
Therapeutic potential of fluoxetine in neurological disorders. CNS Neurosci Ther (2008) 1.00
Admitting acute ischemic stroke patients to a stroke care monitoring unit versus a conventional stroke unit: a randomized pilot study. Stroke (2003) 0.99
Survival effect of first- and second-line treatments for patients with primary glioblastoma: a cohort study from a prospective registry, 1997-2010. Neuro Oncol (2014) 0.99
Intravenous thrombolysis with recombinant tissue plasminogen activator in a stroke patient treated with dabigatran. Cerebrovasc Dis (2010) 0.99
Treatment of essential tremor: a systematic review of evidence and recommendations from the Italian Movement Disorders Association. J Neurol (2012) 0.99
Routine thrombolysis with intravenous tissue plasminogen activator in acute ischaemic stroke patients aged 80 years or older: a single centre experience. Age Ageing (2007) 0.99
Reactive astrocytes in chronic active lesions of multiple sclerosis express co-stimulatory molecules B7-1 and B7-2. J Neuroimmunol (2003) 0.98
Cerebral blood flow velocity changes during upright positioning in bed after acute stroke: an observational study. BMJ Open (2013) 0.98
Immune players in the CNS: the astrocyte. J Neuroimmune Pharmacol (2013) 0.97
Differential cell reaction upon Toll-like receptor 4 and 9 activation in human alveolar and lung interstitial macrophages. Respir Res (2010) 0.97
Interferon beta for secondary progressive multiple sclerosis. Cochrane Database Syst Rev (2012) 0.97
Temporal trends of disability progression in multiple sclerosis: findings from British Columbia, Canada (1975-2009). Mult Scler (2011) 0.97
Long-term persistence with the immunomodulatory drugs for multiple sclerosis: a retrospective database study. Clin Ther (2012) 0.96
Insulin-like growth factor system regulates oligodendroglial cell behavior: therapeutic potential in CNS. J Mol Neurosci (2008) 0.95
The incidence and prevalence of multiple sclerosis in nova scotia, Canada. Can J Neurol Sci (2013) 0.94
Prehospital unassisted assessment of stroke severity using telemedicine: a feasibility study. Stroke (2013) 0.94
Headache associated with cough: a review. J Headache Pain (2013) 0.93
The AMPA antagonist ZK 200775 in patients with acute ischaemic stroke: a double-blind, multicentre, placebo-controlled safety and tolerability study. Cerebrovasc Dis (2005) 0.93
Constitutive overexpression of Norrin activates Wnt/β-catenin and endothelin-2 signaling to protect photoreceptors from light damage. Neurobiol Dis (2012) 0.92
On the origin and evolution of apomixis in Boechera. Plant Reprod (2013) 0.92
Presenting evidence-based health information for people with multiple sclerosis: the IN-DEEP project protocol. BMC Med Inform Decis Mak (2012) 0.92
Fluoxetine increases cerebral white matter NAA/Cr ratio in patients with multiple sclerosis. Neurosci Lett (2006) 0.91
Prehospital stroke care: limitations of current interventions and focus on new developments. Cerebrovasc Dis (2014) 0.91
Oligoclonal bands and cerebrospinal fluid markers in multiple sclerosis: associations with disease course and progression. Mult Scler (2012) 0.91
Perfusion computed tomography in the acute phase of mild head injury: regional dysfunction and prognostic value. Ann Neurol (2009) 0.90
(1)H MR spectroscopy of the brain in multiple sclerosis subtypes with analysis of the metabolite concentrations in gray and white matter: initial findings. Eur Radiol (2005) 0.90
Characterising aggressive multiple sclerosis. J Neurol Neurosurg Psychiatry (2013) 0.90
Cerebral hypoperfusion in multiple sclerosis is reversible and mediated by endothelin-1. Proc Natl Acad Sci U S A (2013) 0.90
Hospital admissions and MS: temporal trends and patient characteristics. Am J Manag Care (2012) 0.90
Serum uric acid levels and leukocyte nitric oxide production in multiple sclerosis patients outside relapses. J Neurol Sci (2005) 0.89
Acute posterior multifocal placoid pigment epitheliopathy with cerebral vasculitis: a multisystem granulomatous disease. Arch Ophthalmol (2006) 0.89
An international case-control study of maternal diet during pregnancy and childhood brain tumor risk: a histology-specific analysis by food group. Ann Epidemiol (2009) 0.89
Uric acid in multiple sclerosis. Neurol Res (2006) 0.88
Free insulin-like growth factor (IGF)-I and IGF binding proteins 2, 5, and 6 in spinal motor neurons in amyotrophic lateral sclerosis. Lancet (2003) 0.88
Astrocytes as potential targets to suppress inflammatory demyelinating lesions in multiple sclerosis. Neurochem Int (2010) 0.88
Astrocytic beta(2)-adrenergic receptors: from physiology to pathology. Prog Neurobiol (2010) 0.87
Neonatal and delivery outcomes in women with multiple sclerosis. Ann Neurol (2011) 0.86
Dietary patterns in clinical subtypes of multiple sclerosis: an exploratory study. Nutr J (2009) 0.86
Thromboelastography in patients with cerebral venous thrombosis. Thromb Res (2009) 0.86
Janus faces of microglia in multiple sclerosis. Brain Res Rev (2007) 0.86
Unassisted assessment of stroke severity using telemedicine. Stroke (2013) 0.85
The insulin-like growth factor system in multiple sclerosis. Int Rev Neurobiol (2007) 0.85
Transmission of Chlamydia pneumoniae infection from blood monocytes to vascular cells in a novel transendothelial migration model. FEMS Microbiol Lett (2005) 0.85
Web search behavior and information needs of people with multiple sclerosis: focus group study and analysis of online postings. Interact J Med Res (2014) 0.85
Pharmacologic treatment of depression in multiple sclerosis. Cochrane Database Syst Rev (2011) 0.85
Insulin-like growth factor binding protein-1 activates integrin-mediated intracellular signaling and migration in oligodendrocytes. J Neurochem (2010) 0.85